Trishula Therapeutics is dedicated to improving outcomes for people with cancer by developing TTX-030, a first-in-class, anti-CD39 antibody.
Our focus is on developing transformational cancer medicines by targeting the mechanisms of immune evasion in the tumor microenvironment. TTX-030, a novel, first-in-class antibody, is currently being studied in phase 1/1b clinical trials.
January 21, 2021
Trishula Therapeutics Appoints Anil Singhal as Chief Executive Officer
August 26, 2020
Trishula Therapeutics Established to Advance Novel TTX-030, and Anti-CD39 Antibody, Being Evaluated in Phase 1/1B Study in Advanced Cancers